SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

​ Conditions: SHR-A1811; HER2-Postive Breast Cancer; HR+ Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer

Interventions: Drug: SHR- A1811

Sponsors: Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting Conditions: SHR-A1811; HER2-Postive Breast Cancer; HR+ Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer
Interventions: Drug: SHR- A1811
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting